ImmunoGen Presents Final Overall Survival and Additional Efficacy Data...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 3, 2023

UNice Celebrates LGBTQ Pride Month • GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting • Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting • High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy • Statement from Minister Hutchings on progress in support of rural Canadians • Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl • New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing • Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT • Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y • Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery • Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin • Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf • Bijou Ikli named new CEO by Florida Assisted Living Association • LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam • 56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line • San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat

ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

WALTHAM, Mass. , March 25 /Businesswire/ - ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.

Oral Presentation Details

Title: Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study

Session: Scientific Plenary I: Progress: Therapeutics Innovations

Session Date: Saturday, March 25, 2023

Session Time: 9:00 am to 10:30 am ET

Additional information can be found at www.sgo.org.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.